Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Tabletop particle accelerator could transform medicine and materials science 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
U.S. Stock Futures Rise as Markets Brace for Jobs and Inflation Data 
Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Asian Currencies Stay Rangebound as Yen Firms on Intervention Talk 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Australian Pension Funds Boost Currency Hedging as Aussie Dollar Strengthens 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
